Physician profile
Timothy Johnson
NPI 1386965622
$14,898.38
in general payments reported to CMS, 2019-2025
25 companies · $5,389 in 2025
The $5,389 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $343 · 2021: $1,326 · 2022: $1,809 · 2023: $1,324 · 2024: $3,189 · 2025: $5,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,328 · Consulting Fee: $3,400 · Travel and Lodging: $2,054 · Entertainment: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,328.37 |
| Consulting Fee | $3,400.00 |
| Travel and Lodging | $2,054.19 |
| Entertainment | $119.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $6,469.39 | 2023-2025 | |
| Alcon Vision LLC | $4,104.44 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Microsurgical Technology, INC. | $700.00 | 2019 | |
| Bausch & Lomb Americas INC. | $687.92 | 2022-2025 | Xiidra, Miebo |
| Iridex Corporation | $485.57 | 2022 | |
| Allergan, INC. | $478.48 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $395.65 | 2020-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Ocular Therapeutix, INC. | $235.44 | 2020-2025 | Dextenza |
| Abbvie INC. | $196.66 | 2022-2025 | |
| Oyster Point Pharma, INC. | $132.88 | 2023 | Tyrvaya |
| Glaukos Corporation | $124.92 | 2021 | |
| Optos, INC. | $119.62 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $118.80 | 2025 | |
| Nova Eye, INC. | $91.51 | 2024 | |
| Dompe US, INC. | $87.23 | 2024 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $82.10 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Astellas Pharma US INC | $75.81 | 2023 | Izervay |
| Omeros Corporation | $65.33 | 2019-2021 | |
| Ivantis, INC | $51.05 | 2019 | |
| Rayner Intraocular Lenses Limited | $50.03 | 2022-2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Derma Sciences, INC. | $43.73 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $39.63 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.89 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.73 | 2022 | |
| Aerie Pharmaceuticals, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.